

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2003

Commission File Number: 0-22286

Taro Pharmaceutical Industries Ltd.

-----  
(Translation of registrant's name into English)

Italy House, Euro Park, Yakum 60972, Israel

-----  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  No

The following is included in this Report on Form 6-K:

1. English summary of the registrant's filings in Hebrew with the Israeli Registrar of Companies during April 2003.

SUMMARY OF FILINGS

During April 2003, Taro Pharmaceutical Industries Ltd. (the "Registrant") filed with the Israeli Registrar of Companies reports of the following issuances of ordinary shares of the Registrant (par value NIS 0.0001 per ordinary share):

SHAREHOLDER	DATE	NUMBER OF SHARES	PRICE PER SHARE (NIS)
Marton Klein	2/27/2003	25	12.05
Dick Guest	3/6/2003	1,250	32.14
Adrian Rebello	3/6/2003	74	11.97
Barry Fishman	3/13/2003	30,000	24.39
Barry Fishman	3/13/2003	1,000	61.78
Silkander Remtulla	3/17/2003	25	11.99
Susi Antoniuk	3/19/2003	25	11.99
Walter Jenkins	3/25/2003	1,000	14.25
Hermona Hills	3/26/2003	4,500	15.89
Tim Conliffe	3/27/2003	25	11.70
Bogumila Lysenko	4/4/2003	50	11.61
Dhaniram Bishundeo	4/7/2003	25	11.56
Alok Sadana	4/7/2003	25	11.56
Karl Nursch	4/7/2003	100	11.33
Karl Nursch	4/7/2003	100	11.56
Hermona Hills	3/26/2003	4,500	15.70
Robert Mauro	4/9/2003	500	11.51

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Taro Pharmaceutical Industries Ltd.

Date: May 19, 2003

By: /s/ Kevin Connelly  
-----  
Kevin Connelly  
Senior Vice President and Chief  
Financial Officer